Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma

(2012) Dingsheng Liu et al.   JOURNAL OF CLINICAL PATHOLOGY

The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

(2011) B. Paiva et al.   BLOOD

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

(2011) J. Martinez-Lopez et al.   BLOOD

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

(2011) G. J. Morgan et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

(2011) G. J. Morgan et al.   BLOOD

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

(2011) G. J. Morgan et al.   HAEMATOLOGICA

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring Residual Myeloma

(2010) Amanda D. Tatsas et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma

(2009) Ritu Gupta et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients

(2009) B. Paiva et al.   BLOOD

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

(2009) Ernesto Pérez-Persona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients

(2009) B. Paiva et al.   HAEMATOLOGICA

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

(2008) Ruben Niesvizky et al.   BRITISH JOURNAL OF HAEMATOLOGY

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

(2008) Juan José Lahuerta et al.   JOURNAL OF CLINICAL ONCOLOGY